MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Low-grade serous ovarian carcinomas (LGSOCs) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are present in 30%-60% of LGSOCs. The purpose of this study was to evaluate binimetinib, a potent MEK1/2 inhibitor with demonstrated activity ac...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 38; no. 32; p. 3753
Main Authors:	Monk, Bradley J, Grisham, Rachel N, Banerjee, Susana, Kalbacher, Elsa, Mirza, Mansoor Raza, Romero, Ignacio, Vuylsteke, Peter, Coleman, Robert L, Hilpert, Felix, Oza, Amit M, Westermann, Anneke, Oehler, Martin K, Pignata, Sandro, Aghajanian, Carol, Colombo, Nicoletta, Drill, Esther, Cibula, David, Moore, Kathleen N, Christy-Bittel, Janna, Del Campo, Josep M, Berger, Regina, Marth, Christian, Sehouli, Jalid, O'Malley, David M, Churruca, Cristina, Boyd, Adam P, Kristensen, Gunnar, Clamp, Andrew, Ray-Coquard, Isabelle, Vergote, Ignace
Format:	Journal Article
Language:	English
Published:	United States 10.11.2020
Subjects:	Adult Aged Benzimidazoles - adverse effects Benzimidazoles - therapeutic use Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - enzymology Cystadenocarcinoma, Serous - pathology Doxorubicin - analogs & derivatives Doxorubicin - therapeutic use Fallopian Tube Neoplasms - drug therapy Fallopian Tube Neoplasms - enzymology Fallopian Tube Neoplasms - pathology Female Humans MAP Kinase Kinase 1 - antagonists & inhibitors MAP Kinase Kinase 2 - antagonists & inhibitors Middle Aged Neoplasm Grading Neoplasm Recurrence, Local - drug therapy Ovarian Neoplasms - drug therapy Ovarian Neoplasms - enzymology Ovarian Neoplasms - pathology Paclitaxel - therapeutic use Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - enzymology Peritoneal Neoplasms - pathology Polyethylene Glycols - therapeutic use Progression-Free Survival Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Topotecan - therapeutic use Young Adult
ISSN:	1527-7755, 1527-7755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!